Human IL-8 (Interleukin 8) ELISA Kit

Name: Human IL-8 (Interleukin 8) ELISA Kit
SKU: DEIA5609
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, plasma, tissue homogenates and other biological fluids.

Species Reactivity

Human

Detection Method

sELISA

Intended Use

For quantitative detection of IL-8 in serum, plasma, tissue homogenates and other biological fluids.

Contents of Kit

1. ELISA Microplate(Dismountable), 8×12, 2-8°C/-20°C
2. Lyophilized Standard, 2vial, 2-8°C/-20°C
3. Sample Dilution Buffer, 20ml, 2-8°C
4. Biotin-labeled Antibody(Concentrated), 120ul, 2-8°C(Avoid Direct Light)
5. Antibody Dilution Buffer, 10ml, 2-8°C
6. HRP-Streptavidin Conjugate(SABC), 120ul, 2-8°C(Avoid Direct Light)
7. SABC Dilution Buffer, 10ml, 2-8°C
8. TMB Substrate, 10ml, 2-8°C(Avoid Direct Light)
9. Stop Solution, 10ml, 2-8°C
10. Wash Buffer(25X), 30ml, 2-8°C
11. Plate Sealer, 5pieces
12. Product Description, 1copy

Storage

2-8°C

Performance Characteristics

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% within the expiration date under appropriate storage condition.

To minimize extra influence on performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is strongly suggested that the same operator performs the whole assay from the beginning to the end.

Precision

Intra-Assay: CV<8%
Inter-Assay: CV<10%

Detection Range

7.813-500pg/ml

Sensitivity

4.688pg/ml

Standard Curve

Results of a typical standard operation of a IL-8 ELISA Kit are listed below. This standard curve was generated at our lab for demonstration purpose only. Users shall obtain standard curve as per experiment by themselves. (N/A=not applicable)

Citations

Have you cited DEIA5609 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

NATURE MEDICINE

Authors: Yuen, Kobe C.; Liu, Li-Fen; Gupta, Vinita; Madireddi, Shravan; Keerthivasan, Shilpa; Li, Congfen; Rishipathak, Deepali; Williams, Patrick; Kadel, Edward E., III; Koeppen, Hartmut; Chen, Ying-Jiun; Modrusan, Zora; Grogan, Jane L.; Banchereau, Romain; Leng, Ning; Thastrom, AnnChristine; Shen, Xiadong; Hashimoto, Kenji; Tayama, Darren; van der Heijden, Michiel S.; Rosenberg, Jonathan E.; McDermott, David F.; Powles, Thomas; Hegde, Priti S.; Huseni, Mahrukh A.; Mariathasan, Sanjeev

Abstract

Although elevated plasma interleukin-8 (pIL-8) has been associated with poor outcome to immune checkpoint blockade(1), this has not been comprehensively evaluated in large randomized studies. Here we analyzed circulating pIL-8 and IL8 gene expression in peripheral blood mononuclear cells and tumors of patients treated with atezolizumab (anti-PD-L1 monoclonal antibody) from multiple randomized trials representing 1,445 patients with metastatic urothelial carcinoma (mUC) and metastatic renal cell carcinoma. High levels of IL-8 in plasma, peripheral blood mononuclear cells and tumors were associated with decreased efficacy of atezolizumab in patients with mUC and metastatic renal cell carcinoma, even in tumors that were classically CD8(+) T cell inflamed. Low baseline pIL-8 in patients with mUC was associated with increased response to atezolizumab and chemotherapy. Patients with mUC who experienced on-treatment decreases in pIL-8 exhibited improved overall survival when treated with atezolizumab but not with chemotherapy. Single-cell RNA sequencing of the immune compartment showed that IL8 is primarily expressed in circulating and intratumoral myeloid cells and that high IL8 expression is associated with downregulation of the antigen-presentation machinery. Therapies that can reverse the impacts of IL-8-mediated myeloid inflammation will be essential for improving outcomes of patients treated with immune checkpoint inhibitors.

IL6 and FAS/FASL gene polymorphisms may be associated with disease progression in HIV-1-positive ethnically mixed patients

JOURNAL OF MEDICAL VIROLOGY

Authors: Loureiro dos Reis, Marilia M.; Queiroz, Maria A. F.; da Silva, Bosco C. M.; da Silva Duarte, Alberto J.; Arganaraz, Gustavo A.; Vallinoto, Antonio C. R.; Arganaraz, Enrique R.

Abstract

The progression of AIDS depends on the complex host and virus interactions. The most important disease progression hallmarks are immune activation and apoptosis. In this study, we address the prevalence of polymorphisms related to proinflammatory and apoptotic genes, such as IFNG (+874T/A), TNF (308G/A), IL6 (-174G/C), IL8 (-251A/T), FAS (-670A/G), and FASL (-124A/G) in 160 ethnically mixed HIV-1-infected patients from multicentre cohorts with different clinical outcomes (13 elite controllers [EC], 66 slow long-term non-progressors [LTNPs], and 81 progressors [P]). The genotyping was accomplished by TaqMan-qPCR. Among all the polymorphisms analyzed in the cytokines, the IL6 -174G/C polymorphism showed a higher frequency of GG genotype in the LTNP and LTNP+EC groups as compared to the P group. Moreover, there was a significantly higher frequency of the G allele in the LTNP and LTNP+EC groups as compared to the P group. On the other hand, the levels of CD4(+) T lymphocytes were higher among individuals showing the AA and AG genotypes for the FASL -124A/G polymorphism as compared to the GG genotype. Furthermore, the AG and AA genotypes were more frequent, as compared to the GG genotype, in individuals showing a lower viral load. In contrast, for the FAS -670A/G polymorphism, a significantly higher viral load was observed in individuals with the AG genotype as compared to the GG genotype. In conclusion, we found three genetic allelic variants of the IL6 -174G/C, FASL -124A/G, and FAS -670A/G polymorphisms that were related to disease progression and immunological and virological markers in cohorts of HIV-1-positive ethnically mixed patients.